br Diacylglycerol kinases and T cell responses br
Diacylglycerol kinases and T cell responses
Diacylglycerol kinases and cancer Several studies implicate DGKα in tumor progression, but its function is debated, as it might also have roles as a tumor suppressor. Diminished DGKα expression is linked to malignant transformation in epithelia. High DGKA expression relates to lung cancer patient survival and decreased expression is synergistic with p53 and Ras mutations in colon cancer (Berrar et al., 2005, Kong et al., 2016, McMurray et al., 2008). The reported regulation of DGKα by FoxO supports a causal relationship between reduced DGKα expression and oncogenic transformation. Diminished DGKα expression as the result of oncogenic activation of PI3K/AKT pathways, would result in a concomitant loss of its DAG-break functions providing activation of additional pathways linked to transformation.These observations Illumina 384 with enhanced DGKα expression in hepatic tumors when compared to adjacent non-cancerous tissue, which does not express this isoform (Takeishi et al., 2012, Yanagisawa et al., 2007). DGKα exppression is higher also in metastasis of the original tumor (Hao et al., 2004, Marchet et al., 2007). When mutated, DGKα is a causative gene in pancreatic cancer (Carter et al., 2010), and was recently described as a potential target for glioblastoma treatment (Dominguez et al., 2013). DGKα mediates numerous aspects of cancer cell progression including survival (Bacchiocchi et al., 2005, Takeishi et al., 2012, Yanagisawa et al., 2007), migration and invasion (Baldanzi et al., 2008, Filigheddu et al., 2007, Rainero et al., 2012). These studies suggest that some tumors develop an “addiction” for DGKα regulated pathways. The concept of “non-oncogenic addiction”, first formulated by Solimini et al. (Solimini et al., 2007), relates to a wide array of signaling enzymes that, albeit not inherently malignant, provide survival advantages to tumors. It usually relates to stress response mechanisms and contribute to drug resistance in many tumors. Targeting these pathways represent a promising approach in cancer since it provides means of selectively targeting tumor cells sparing non-transformed tissues.
Conclusions The more recent studies have identified the upregulation of DGKα and DGKζ as mechanisms that may contribute to tumor induce T cell tolerance. The increased DGKα expression observed in metastatic tumors probably reflects the acquisiton of new traits and correlates with the reported function of Src in metastasis. In contrast with its downregulation in the inital steps of transformation, the model predicts DGKα upregulation in response to stress conditions, such as limited nutrient availability or chemotherapy treatments. In this latter case, our data demonstrate that DGKα expression, upregulated in response to PI3K/Akt inhibition, contributes to Src activation, and provide additional proof of DGKα as part of tumor escape mechanisms. A model thus emerges where the same microenviroment conditions will favor DGKα expression both in tumor and T cell tissue with opposite consequences (Fig. 4). DGKα in the tumor will foster survival and metastatic traits whereas the same enzyme in T cells will favor anergic behaviors. New drug therapies targeting this lipid kinase would prevent DGKα contribution to tumor survival, drug resistance and immune escape mechanisms; three conditions that may occur at different stages as tumor evolve to a more transformed phenotype (Fig. 5). The efficacy of isoform specific inhibitors vs. pan-DGK inhibitors as well as the potential use of targeting DGK in combination with other checkpoint-blocking agents and/or other anticancer therapies will be with no doubt the object of intense future studies.
Funding JAN hold a predoctoral fellowship from Spanish Ministry of Economy and Competitiveness (MINECO), MTL is a Formación de Personal Investigador fellows and EA is a Formación de Profesorado Universitario fellow of the Spanish Ministry of Education. This work was supported in part by grants from the Spanish Ministry of Economy and Competitiveness (BFU 2013-47640P), the Spanish Ministry of Health (Instituto de Salud Carlos III; Cancer Program Grant RD12/0036/0059), and the Madrid regional government (IMMUNOTHERCAM S2010/BMD-2326) to IM.